Sarah Smith

Sarah Smith

Expertise: ESG Investing, Electric Vehicle Stocks, Short Squeeze Stocks

Education: BA, Government and Gender, Sexuality and Women’s Studies, The College of William & Mary

Awards & Accomplishments: Top 5% of stock pickers on TipRanks

About Sarah:
Sarah Smith is an experienced editor and writer who works to help retail investors make sense of what’s happening every day on Wall Street, and she’s particularly interested in ESG investing, EV stocks, and the rise of speculative trading activity like short squeezes. She has also written for Kiplinger.com, Smithsonian, and Washington City Paper. Sarah is currently working to become a Chartered Financial Analyst (CFA) and has already earned bachelor’s degrees in Government and Gender, Sexuality and Women’s Studies from the College of William and Mary. Her work for InvestorPlace.com focuses on helping investors understand the causes and impacts of daily stock and crypto market movements, and how a disruption in who invests – and how they invest – transforms the market. Sarah is recognized among the top 5% of stock pickers on TipRanks and has an average return of 50%. She lives in Arlington, Virginia.

Connect with Sarah on LinkedIn.

Recent Articles

HMNY Stock Back From the Dead? MoviePass Countdown Fuels Social Media Speculation

In an already whirlwind year, it seems that MoviePass could be coming back from the dead. Helios and Matheson Analytics (OTCMKTS:HMNY), its parent company, could…

What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.

What did the stock market do today? Investors were focused on top SPAC names, Fed moves and some crypto drama.

What Will the Stock Market Do Today? 3 Big Stories to Watch.

What will the stock market do today? It sounds like investors will be watching cruise stocks and plays for the revenge economy.

What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.

What did the stock market do today? Investors focused on speculative vaccine plays, cannabis stocks and reopening rallies.

OCGN Stock: Red-Hot Ocugen Eyes U.S. Vaccine Launch in Q2

OCGN stock just got a big boost. According to a new report, Ocugen plans to launch its Covid-19 vaccine in the U.S. soon.